Posts Tagged ‘medical Marijuana’

Supreme Completes First Tranche of Previously Announced Private Placement

Posted by AGORACOM-JC at 8:54 AM on Monday, September 22nd, 2014

VANCOUVER, BRITISH COLUMBIA–(Sept. 22, 2014) –

NOT FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.

Supreme Pharmaceuticals Inc. (“Supreme” or the “Company“) (CSE:SL) is pleased to announce that it has closed the first tranche of its previously announced unit financing (see news releases dated August 15^th and September 4, 2014) for total gross proceeds of $2,239,232.50 (the “Financing“). At closing, Supreme issued 8,956,930 Units (comprised of 8,956,930 common shares of the Company (“Common Shares“) and 4,478,465 Common Share purchase warrants (“Warrants“)) at a price of $0.25 per Unit. Each Warrant is exercisable for one Common Share at a price of $0.50 per share prior to September 22, 2015, subject to an accelerated expiry period upon 30-days notice by the Corporation to the subscriber, if the Common Shares trade at or above $0.70 for any five (5) day period during the term of the Warrants. Directors, senior officers and other insiders of the Corporation purchased an aggregate of 660,000 Units pursuant to the Financing. The Company paid finder’s fees of $65,320 and issued 287,280 Warrants to certain arm’s-length parties in the connection with the subscriptions of certain subscribers who participated in the private placement.

The Common Shares and Warrants issued pursuant to the private placement are subject to a hold period that expires January 23, 2015. Following closing, Supreme has 68,341,565 Common Shares issued and outstanding.

The Company intends to use the proceeds of the Financing for the development of the Company’s Kincardine facility and general working capital purposes. Based on the number of investors who have already submitted subscription agreements for the final tranche of the Financing, Supreme anticipates moving quickly towards a second closing prior to the end of September.

FORWARD-LOOKING INFORMATION

This news release contains forwardâ€looking statements and forwardâ€looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forwardâ€looking statements or information. More particularly and without limitation, this news release contains forwardâ€looking statements and information relating to the use of proceeds of the private placement, as well as the Company’s corporate strategy, participation in second tranche by those investors who have submitted subscription agreements to the Company but were not included in the first tranche, and having sufficient subscribers to close a second tranche. The forwardâ€looking statements and information are based on certain key expectations and assumptions made by management of the Corporation, including, without limitation, the Company’s ability to complete the remainder of the private placement. Although management of the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forwardâ€looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Corporation relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forwardâ€looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should not place undue reliance on the forwardâ€looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forwardâ€looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forwardâ€looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191
[email protected]
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on Supreme Completes First Tranche of Previously Announced Private Placement

Lexaria Submits Health Canada Marijuana License Application

Posted by AGORACOM-JC at 8:16 AM on Wednesday, September 17th, 2014

Health Canada Marijuana License Application Submitted

Kelowna, BC / ACCESSWIRE / September 17, 2014 / Lexaria Corp. (LXRP-OTCQB) (LXX-CNSX) (the “Company” or “Lexaria”) reports that the joint venture with Enertopia Corp has submitted the Health Canada MMPR Licensed Producer application in July 2014, and that the application is currently in the Health Canada preliminary screening process. The actual submission of our license application had not been previously disclosed.

The Joint Venture is in correspondence with Health Canada frequently with respect to specific aspects of the licensing process which are being handled by Ontario Operations Manager Mr. Donald Shaxon, responsible person in charge. The Joint Venture has requested a Ready to Build letter from Health Canada.

The Burlington Joint Venture with Enertopia Corp (ENRT or TOP) has applied to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49%, as earlier disclosed.

The Burlington JV has requested a Ready to build letter from Health Canada once the application has been accepted from Health Canada.

Listed below are the Health Canada steps for becoming a licensed producer to be reached by way of the application and review process. There are no specific process time constraints for each step.

Step 1: Preliminary Screening
Step 2: Enhanced Screening
Step 3: Security Clearance
Step 4: Review
Step 5: Ready to build letter (if required by applicant)
Step 6: Pre-licence inspection
Step 7: Licensing

Health Canada has also been clear about the quantity of licenses to be issued, in contrast to certain marketplace speculation. The Health Canada website asks the question, “Is there a limit to how many production licences Health Canada will issue under the Marihuana for Medical Purposes Regulations (MMPR)?” And Health Canada answers the question with, “No. Health Canada will not impose a limit on the number of production licenses.”

Lexaria provides the above information to provide guidance and clarity to counter what at times appear to be flawed information in the community, of course acknowledging that the policies of third parties can change at any time.

The Joint Venture has been active in the local community and has met with the local policing authority, which is interested in conducting security training and swat team training at the Joint Venture facility. We are very pleased to be working closely with law enforcement and look forward to learning more from preventative and proactive security measures.

Lexaria also notes that the Ottawa project has conducted due diligence on and rejected the initial proposed building location in the greater Ottawa area as not likely to comply with the strict requirements of the MMPR. Additional locations in the area are being examined. The company will remain prudent in its efforts to ensure the maximum return on all our stakeholder’s investments.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana business will provide any benefit to Lexaria and no assurance that the corporate policies described herein will produce any benefit for the Company or its shareholders. There is no assurance that Health Canada will grant any license or ready to build letter to the Company at any time, with respect to the Company’s MMPR application.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Corp.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, medical Marijuana
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Submits Health Canada Marijuana License Application

Enertopia Provides Burlington Lexaria JV Update

Posted by AGORACOM-JC at 8:11 AM on Wednesday, September 17th, 2014

VANCOUVER, BC / September 17, 2014 / Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) announces the Burlington, Ontario Application is in the Health Canada Preliminary Screening process.

The company is pleased to advise shareholders that its Joint Venture partner, Lexaria Corp (LXRP), and the Company have submitted their application for Licensed Producer in July 2014 and are in regular correspondence with Health Canada with respect to specific aspects of the licensing process, which are being handled by Ontario Operations Manager Mr. Donald Shaxon as responsible person in charge.

The Burlington Joint Venture with Lexaria Corp has applied to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49% as disclosed on April 9, 2014 in Enertopia’s press release #201424.

The Burlington JV has requested a Ready to build letter from Health Canada once the application has been accepted from Health Canada, see step 5 below.

For those not familiar with the Health Canada process for becoming a licensed producer, below are the levels to be reached through the application process. Note there are no specific process times for each step, however one could progress from preliminary screening to ready to build letter in as little as 90 to 120 days depending on the application submitted to Health Canada:

The Joint Venture (JV) has been active in the local community and has received very good community and media support. The JV also met with the local policing authority and upon licensing by Health Canada we have proposed that the local police could conduct security and swat team training at the facility. We are very pleased to be working closely with law enforcement and look forward to their insights in preventative and proactive security measures.

Enertopia at this time publically acknowledges its support for the Lexaria Corp policy on the responsible use of medical marijuana announced on August 28, 2014. Therefore, Enertopia is establishing a corporate policy wherein we will not knowingly sell medical cannabis containing more than 0.3% THC to any medical marijuana patient who is under the age of 21, unless it is in a form specifically approved by relevant government health agencies.

“Enertopia’s overriding responsibility is to cause no harm and keep Medical Marijuana as a safe and secure option for patients in search of natural healing options.” Stated President / CEO Robert McAllister.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Ken Faulkner, Business and Institutional Development: (250) 765-3630

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential licensing and financing of its medical marihuana projects, evaluation of clean energy projects, oil & gas projects, , competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Burlington Joint Venture will obtain a license under MMPR and or that the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Enertopia, Enertopia Corp., Medical Marijuana Stocks | Comments Off on Enertopia Provides Burlington Lexaria JV Update

Enertopia Provides Update on The Green Canvas JV

Posted by AGORACOM-JC at 8:04 AM on Tuesday, September 16th, 2014

VANCOUVER, BC / September 16, 2014 / Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) Green Canvas Application is in the Health Canada preliminary screening process.

The company is pleased to advise shareholders that it has been informed by its Joint Venture partner The Green Canvas that they have submitted their application for Licensed Producer and are in correspondence with Health Canada with respect to specific aspects of Quality Assurance Reports which are being handled by their in house PH.D in Organic Chemistry in the application process.

The Green Canvas has applied to produce 10,000 kg of Medical Marihuana per year under its Licensed Producer application. Enertopia may acquire up to a 75% interest in the joint venture as disclosed on February 28, 2014 in our press release 201412.

Facility upgrades are ongoing and Enertopiaâ€™s Management team will be onsite in early October and will provide a project update shortly thereafter.

For those new to the Health Canada process for becoming a licensed producer below are the levels to be reached through the application process, Note there are no specific process times for each step:

â€œThe Green Canvas is well known and respected in their outreach to patients in need of Medical Marihuana and are respected for producing the highest quality of medical grade marihuana.â€ Stated President / CEO Robert McAllister.

Further information on the Green Canvas can be found at www.thegreencanvas.ca/

About Enertopia

Enertopiaâ€™s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Ken Faulkner, Business and Institutional Development: (250) 765-3630

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation of clean energy projects, oil & gas projects, , competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Green Canvas Joint Venture will obtain a license under MMPR and or that the Company will be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana, Medical Marijuana stocks
Posted in Enertopia, Enertopia Corp. | Comments Off on Enertopia Provides Update on The Green Canvas JV

Next Gen to Reschedule the Seattle GreenRush Financial Conference

Posted by AGORACOM-JC at 7:09 PM on Friday, September 5th, 2014

VANCOUVER, BRITISH COLUMBIA–(Sept. 5, 2014) – Next Gen Metals Inc. (“Next Gen”, the “Company”) (CSE:N)(PINKSHEETS:NXTTF)(FRANKFURT:M5BN) reports that due to numerous requests by both exhibitors and attendees to change the conference to a two day format, management has made a decision to postpone the Seattle GreenRush Financial Conference scheduled for September 23rd, 2014 to a later date. The company is actively seeking a suitable venue/date to accommodate these format changes. Management will issue a news release announcing all new developments for the conference at such time as they become available. In the event that the company is unable to secure a suitable venue and/or date this fall for Seattle, it will continue to focus on scheduling a full slate of conferences for the 2015 conference season including Seattle. The Company apologizes for any inconvenience this decision may have caused and asks that those who have been affected to please contact the Company at either 1-800-667-1870 or 604-685-1870.

Next Gen looks forward to expanding our presence; not only in North America, but also internationally as other countries continue to champion the legalization of Cannabis. Within North America, the company’s future conferences will be coordinated with those states that are in the process of Legislating the legalization of Cannabis.

About Next Gen

Next Gen is a diversified Canadian public company which focuses on investing in the Medical Marijuana, Industrial Hemp and Alternative Medicine sectors. Recent regulatory/legal changes in North America have provided an opportunity for the company to enter into this emerging multiâ€billion dollar industry. Next Gen’s vision is to be the leading provider of venture capital, management expertise, education, brokerage and consultancy solutions and a facilitator for these explosive new industries.

Next Gen’s business model generates new industry business proposals and plans on a continuous basis. To that end, Management is currently developing two wholly owned subsidiaries, GreenRush Financial Conferences and GreenRush Analytical Laboratories. Management is negotiating with a number of companies who are interested in entering into contractual arrangements to coâ€venture, coâ€finance, and optionâ€joint venture on one or more of Next Gen’s large inventory of business opportunities and existing 100% owned companies and projects in these multiâ€billion dollar industries.

For further information on the company, visit our website at www.NextGenMetalsInc.com.

On behalf of the Board of Directors

Harry Barr, President & CEO

FORWARD-LOOKING INFORMATION: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this news release.

Toll Free: 1.800. 667. 1870
Main: + 1 (604) 685. 1870
Fax: + 1 (604) 685. 8045
www.nextgenmetalsinc.com

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Medical Marijuana Stocks, Next Gen | Comments Off on Next Gen to Reschedule the Seattle GreenRush Financial Conference

Supreme Updates Financing and Announces Launch of New Website

Posted by AGORACOM-JC at 9:05 AM on Thursday, September 4th, 2014

VANCOUVER, BRITISH COLUMBIA–(Sept. 4, 2014) – Supreme Pharmaceuticals Inc. (the “Company”) (CSE:SL) wishes to announce its intention to offer securities under of the previously announced non-brokered private placement (see news release dated August 15^th, 2014) of up to 20 million units in the capital of the corporation (“Units”) at a price of $0.25 per Unit for aggregate gross proceeds of up to $5,000,000 (the “Financing”) to existing holders of common shares of the Corporation (“Existing Shareholders”). Any Existing Shareholder of Supreme as at September 3, 2014 will be eligible to purchase Units pursuant to the recently adopted “existing security holder” prospectus exemption in all Canadian jurisdictions other than Ontario and Newfoundland. Under the new regulation, there is no longer a need for an existing shareholder to qualify under the “accredited investor” exemption in order to participate in the Financing, however subscribers who do not receive advice regarding the suitability of their investment from a registered investment dealer may not purchase more than $15,000 of securities of Supreme under this exemption in any 12 month period.

In the event there is an over subscription of shares, the Company reserves the right to either reject subscriptions at its discretion, allocate on a pro rata basis or increase the size of the Financing. It is anticipated that the offering will be open until September 19^th, 2014.

A director of the Company stated, “The amendment to the financing is an avenue that allows us to include our valued shareholders that wish to participate in our current placement. In addition, the new brand and fully integrated website bring the Company one step closer to its goal of becoming a commercial producer of medical marijuana.”

In addition, the company pleased to report that it has recently undergone a major rebranding and developed a new website infrastructure complete with online store, corporate information, news, doctor’s hub, and more. The new brand and website are anticipated to launch on Monday, September 8^th, 2014 at www.supreme.ca.

FORWARD-LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the closing date of the Offering, the availability of the “existing security holder” exemption for purchases of Units under the Financing and the launch date for the new website. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to close the offering, the Units not being eligible for purchase through certain exemptions from the prospectus requirement and failure to launch the website as anticipated. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995..

Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191
[email protected]
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on Supreme Updates Financing and Announces Launch of New Website

Smoking hot marijuana stocks could give investors a buzz

Posted by AGORACOM-JC at 11:41 AM on Tuesday, September 2nd, 2014

Dilys Chan, BNN.ca staff
10:53 AM, E.T. | August 30, 2014
Canadian, Energy & Resources

Itâ€™s an exciting time for medical pot in Canada. Two new licensed medical marijuana companies started trading on Monday: OrganiGram Holdings Inc. (OGI.VÂ 2.27Â 0.02Â 0.89%) and Bedrocan Cannabis Corp. (BED.VÂ 1.12Â 0.04Â 3.7%). They joined Tweed Marijuana Inc. (TWD.VÂ 2.45Â -0.02Â -0.81%) on the TSX Venture Exchange, bringing the total number of publicly traded marijuana stocks in Canada to three. Both of the new stocks ended the week above their opening prices.

The trend in the commodities space will continue with a fourth company, Mettrum, to hold an IPO in September. According to Khurram Malik, a research analyst at Jacob Securities, the fledgling licensed marijuana industry is at very early stages of enormous growth.

â€œThe [companies] on the Venture exchange with licenses â€“ theyâ€™re going to go from $0 to $10 million in revenue pretty quickly in the next year. Tweedâ€™s a perfect example. Theyâ€™ll have 12 grow rooms up and running by the end of the year,â€ said Malik.

â€œThe question over the next few months is how quickly suppliers can get their act together and start getting their supply in the market. It is a bit tricky to produce marijuana at a large scale.â€

Producers who can ramp up capacity, production and revenue quickly enough can tap into a target market that could potentially generate $1.8 billion in annual revenue, he said to BNN.

The cannabis plant can be a legitimate treatment option for over 100 ailments, said Malik, with pain relief being a common use. With an estimated 500,000 medical pot users in Canada and only 13 suppliers licensed by Health Canada, there is significant demand for product.

â€œThese are very profitable investments for investors to be getting exposure to,â€ he said.

Investors can compare two key metrics of companies as the industry matures, Malik said. The first is cost to grow product, measured in dollar per gram. The second is how effectively the company acquires customers, a metric that will become more important as producers seek to differentiate themselves from their competition.

Ultimately, Malik thinks marijuana will be legalized, though itâ€™s unclear when that will happen. In the meantime, a regulatory challenge for producers is that they canâ€™t market directly to the consumers or open storefronts. Potential customers need a medical document, similar to a prescription, which then allows them to choose a supplier. But, they have to research and find the supplier on their own. The industry depends on its consumers being self-educating.

Despite that inconvenience, Malik isnâ€™t worried about demand being low for medical pot.

â€œBuying from the legitimate producers is cheaper, itâ€™s a higher quality and itâ€™s more convenient than going to your proverbial street corner and buying it black market at twice the price.â€

Source: http://www.bnn.ca/News/2014/8/30/Smoking-hot-marijuana-stocks-could-give-investors-a-buzz.aspx

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Enertopia, Enertopia Corp., Lexaria Corp., Medical Marijuana Stocks, Next Gen | Comments Off on Smoking hot marijuana stocks could give investors a buzz

Supreme Pharmaceuticals Inc. Announces Brayden R. Sutton as Executive V.P

Posted by AGORACOM-JC at 11:16 AM on Thursday, August 28th, 2014

VANCOUVER, BRITISH COLUMBIA–(Aug. 28, 2014) – Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (OTCBB:SPRWF)(CSE:SL) is pleased to announce Brayden R. Sutton as Executive Vice President.

Mr. Sutton will be responsible to oversee operations, assisting in the overall design and completion of the facilities, marketing, financing and business development.

Mr. Sutton has been involved on the research and analysis side of cannabis and cannabis related businesses for over 10 years. Brayden has a thorough understanding of the science of cannabis, the patients who use it, and close ties to the physician community.

He brings over 12 years of successful experience in the capital markets as an investor and financier since 2002 as well as extensive management and operational experience overseeing large-scale projects. He is also President and CEO of CannabisHealth.com as well as having served as the only Canadian Analyst for 420Investor.com.

David Stadnyk, President and CEO stated:

“We are very pleased Brayden is joining the Company as he will be a great addition to our management team with his thorough knowledge of the industry and deep understanding of our business”.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the up grading of the facility, the timing on completion of the MMPR License conditions and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to finish the upgrading of the facility and put the same into production in accordance within the terms of the MMPR license. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
430 – 580 Hornby Street, Vancouver BC, V6C 3B6
604.674.2191
[email protected]
www.supremepharmaceuticals.com

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on Supreme Pharmaceuticals Inc. Announces Brayden R. Sutton as Executive V.P

Lexaria Announces Responsible Marijuana Policy

Posted by AGORACOM-JC at 8:06 AM on Thursday, August 28th, 2014

KELOWNA, BC / August 28, 2014 / Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria” or â€œourâ€ or â€œLexaria CanPharm Corpâ€) announces our new corporate policies regarding the responsible use of medical marijuana.

In Canada, the MMPR legislation governed by Health Canada provides the framework by which qualified persons can access marijuana for medical purposes. Recently, the Supreme Court of British Columbia has also ruled that medical marijuana is a constitutional right for persons in need, deliverable in forms commonly referred to as â€œoils and ediblesâ€. Lexaria intends to comply with the laws and regulations within every jurisdiction in which it might operate.

In addition, it is our philosophy to recognize the potential for harm within this sensitive industry and to build a set of corporate policies that go above and beyond those required by law. Lexaria is leading the industry with these policies.

Therefore, Lexaria is establishing a corporate policy wherein we will not knowingly sell medical cannabis containing more than 0.3% THC to any medical marijuana patient who is under the age of 21, unless it is in a form specifically approved by relevant government health agencies.

â€œOur goal is to safely help people live healthy and productive lives,â€ said Chris Bunka, CEO of Lexaria. â€œWe want to be sure to do no harm and Lexariaâ€™s policies are a big step in the right direction – ensuring members of our community are receiving the health benefits they need.â€

Broadly speaking, there are two main â€˜familiesâ€™ of active ingredients in marijuana: THC (Tetrahydrocannabinol) which have primarily psychoactive properties accompanied by possible medicinal qualities; and CBD (Cannabidiol) which are believed to have more significant medicinal properties and do NOT generally have psychoactive properties. Introductory information about Cannabidiol can be found at Wikipedia at http://en.wikipedia.org/wiki/Cannabidiol

Our underage policy makes Lexariaâ€™s and Lexaria CanPharmâ€™s medical marijuana sales policies more restrictive than Canadaâ€™s alcohol consumption laws; and broadly in line with the USAâ€™s alcohol consumption laws. We believe it would not be responsible to provide medical marijuana with THC-psychoactive properties to underage persons, so long as there is a CBD-based available alternative with medical properties that can meet a potential patientâ€™s needs. We would welcome any development that sees the medical marijuana industry sector follow our lead on this issue and restrict the selling of marijuana containing THC to underage persons.

Many health care practitioners are reluctant to support the use of medical marijuana in underage patients, and it is our hope that our underage policy helps to address those concerns.

Also, Lexaria does not encourage nor support consuming marijuana through the act of smoking. Some research has indicated that the act of burning marijuana may negatively affect the delivery of potentially helpful CBD-based compounds, and smoking any substance is not conducive to good health practices. Lexariaâ€™s policy, for those who require medical marijuana, is to encourage its consumption through edible and other legal forms that do not require smoking.

Lexaria encourages persons across Canada or in the USA whose philosophy regarding the responsible use of marijuana is in accordance with our own, to register at our website (www.lexariaenergy.com). Lexaria wishes to build a community of like-minded, responsible medical users of marijuana who can share their experiences and knowledge with each other for the benefit of all. Lexaria CanPharm Corp is in the development stages of a new website which will be announced when complete.

Lexaria reminds all parties that it does not currently posses a production license under Health Canadaâ€™s MMPR program, nor in any other jurisdiction, and cannot fill any medical marijuana prescription orders at this time.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.

Chris Bunka

Chairman & CEO

(250) 765-6424

FORWARD-LOOKING STATEMENTS

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Announces Responsible Marijuana Policy

AGORACOM Welcomes Supreme Pharmaceuticals (SL: CSE) Canada’s Newest Entrant to $1.3B Medical Marijuana Industry

Posted by AGORACOM-JC at 10:53 AM on Monday, August 25th, 2014

SL: CSE

Supreme Pharmaceuticals Inc. dedicated to securing multiple producing medical marijuana facilities in Canada and applying for several MMPR commercial production licences.

South Okanagan Producing Facility

About The Facility

The Vendor currently owns its own facility in Okanagan Falls, British Columbia. The Vendor has cost effectively facilitated Personal-use Production License holders production of monthly crops of approximately 16,000 grams/month of medical marihuana in full compliance with all regulatory authorities. In the application for the MMPR, the company has applied for a significantly larger amount for commercial production.

The medical marijuana currently produced by private license holders requires a strictly controlled and augmented growing environment to consistently reach optimal plant characteristics in 90 days. The Vendor has designed and constructed 3 indoor purpose specific greenhouses, each of which are planted monthly, and harvested at 90 days.

Each greenhouse is fully climate controlled, with all key growing elements monitored and computer controlled to ensure consistent production. There are production elements, which require brief manual monitoring and intervention on a daily basis, but all key environmental functions are electronically controlled. The details of the process are highly commercially sensitive and valuable, and will not be disclosed until a full sale transaction is concluded.

The facility has been built to be fully compliant with all relevant building and safety requirements. All electrical, plumbing, security, and related plant and equipment are built to full commercial standards.

The facility has received and replied to the Department of Health Canada on its Marihuana for Medical Purposes Regulations Licence (MMPR) application, who required additional information on:

External and internal security measures
Updated site survey and aerial photographs
Further information on principal and proposed technical employees
Details on record keeping and information handling procedures

The Vendor has engaged external consultants and specialists to assist in the application process who have been able to respond and provide the requested documentation in a timely manner. While the Vendor is confident that their prior experience and expertise in the industry and the high commercial standards of the production facility will enable full compliance with Department of Health requirements for a full commercial MMPR license, there is no guarantee a MMPR license will be granted.

Management of Supreme and its operating subsidiary recently met with government officials, including the fire chief, local politicians, and community stakeholders in the township where its Southern Ontario green house facility (Facility 2) is located. The Company does not foresee any concerns in this area as construction progresses such that it may eventually receive final receipt of the MMPR license.

Gupta: ‘I am doubling down’ on medical marijuana

Dr. Sanjay Gupta, CNN Cheif Medical Correspondent. We have no affiliation with this well known medical expert, but his latest “Doubling Down” on the medical marijuana sector is worthy of your attention. Reasons such as these convince us we are doing the right thing in entering this market.

Medical marijuana and ‘the entourage effect’

12 Month Stock Chart

Tags: #smallcapstocks, $TSXV, CSE, medical Marijuana
Posted in Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on AGORACOM Welcomes Supreme Pharmaceuticals (SL: CSE) Canada’s Newest Entrant to $1.3B Medical Marijuana Industry

AGORACOM Small-cap Investor Relations Blog